CALAVO GROWERS INC
CVGWInvestment snapshot
Positive
1
BUY / PASS
Neutral / negative
5 / 10
NEUTRAL / FAIL
Median fair value
$11.11
-59.8% vs price
Models with upside
1 / 17
Positive margin of safety
Strongest signal
10 of 12 pass — Graham and Lynch object
Key risk
15 of 16 flag CVGW's profitability — Graham, Buffett, Lynch +12 more
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #1201 (Top 38.8%) | NEUTRAL | FAIL | NEUTRAL | FAIL | FAIL | FAIL | FAIL | PASS | NEUTRAL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||||
| Margin of Safety | -62.5% | -65.5% | N/A | -286.4% | N/A | -852.8% | -154.0% | -120.3% | +2.7% | -162.6% | -148.7% | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-01-31 · Balance sheet at 2026-01-31 · Annual history · FY 2025 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-01-31 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-01-31 · TTM ended 2026-01-31 vs 2025-01-31 · TTM ended 2026-01-31 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-01-14 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-01-14 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-01-31 · Balance sheet at 2026-01-31 · Market data at 2026-04-10 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-01-31 · Balance sheet at 2026-01-31 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-01-14 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-01-31 · Balance sheet at 2026-01-31 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-01-31 · Qualitative assessment Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-01-31 · Balance sheet at 2026-01-31 · Market data at 2026-04-10 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-04-10 · Balance sheet at 2026-01-31 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-01-14 Score computed: 2026-11-14 | TTM ended 2026-01-31 · Balance sheet at 2026-01-31 · Price history 2025-01-01–2026-04-10 · Annual history · FY 2025 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-01-31 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-01-31 Latest source filing: 2026-03-12 Score computed: 2026-11-14 | TTM ended 2026-01-31 · Annual history · FY 2025 · Price history 2025-01-01–2026-04-10 Latest source filing: 2026-03-12 Score computed: 2026-11-14 |
Where It Passes
- Debt & Leverage83% pass✓ 13✗ 2▾
10 of 12 pass — Graham and Lynch object
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.02, IC: 17.7x✓BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.02✓Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities2.21✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.02✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0.02✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=17.7x, D/EBITDA=0.2x✓MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.02✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.0231; #782/4210 (top 18.6%)✓AsnessTop 30% of eligible cross-section
Where It Falls Short
- Profitability6% pass✓ 7✗ 28▾
15 of 16 flag CVGW's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)22/28 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)21/28 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-0.6%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)3.0% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$25.1M✓BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE7.8%✗Lynch> 15%EBIT / Enterprise Value4.5%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=4.5%, ROC=25.4%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets6.77%✓PiotroskiROA > 0ROA Change YoY-0.36% -> 6.77% (delta: +7.13%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=7.37%, ROA=6.77%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY10.2% -> 9.8%✗PiotroskiImproved YoYPre-Tax Income / Revenue3.5%✗Dreman>= 8%Net Income / Shareholders' Equity7.8%✗Dreman> 12%Margin of SafetyP/E=24.9x, P/B=2.4x✗PabraiP/B < 1.5 or P/E < 15Return on Equity1.7% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value-852.8% (IV=$2.90 vs Price=$27.63)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency21/27 years positive✓MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue2.1%✗Ackman>= 15%Net Income / Shareholders Equity7.8%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend2.1% (2023) -> 3.0% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 10.5% -> 9.8%, operating margin 2.1% -> 3.0%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization+3.28%; #2280/6340 (top 36.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+21.17%; #1986/3702 (top 53.6%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity+7.84%; #2112/5226 (top 40.4%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0347; #2097/5884 (top 35.6%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR190.8% over 5 years✗Neff7%-20% annualizedPositive Diluted-EPS Years5/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Valuation8% pass✓ 2✗ 26▾
12 of 13 flag CVGW's valuation — Graham, Lynch, Greenblatt +9 more
Price / 3-yr avg EPS142.9x✗Graham<= 15xPrice-to-Book Ratio2.4x✗Graham<= 1.5xP/E x P/B341.10✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value4.5%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=4.5%, ROC=25.4%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS24.9x✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)22.9x✗Dreman< 8xPrice / Book Value per Share2.4x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessP/E=24.9x, OE Yield=5.1%✓MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldP/E=24.9x, FCF Yield=4.0%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/E=24.9x, P/B=2.4x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value-852.8% (IV=$2.90 vs Price=$27.63)✗Marks>= 20% below intrinsic valuePrice / FCF per Share25.5x✗Ackman<= 25Price vs. Trailing Low✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization+3.28%; #2280/6340 (top 36.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.4191; #3190/6449 (top 49.5%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS24.9x✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E7.78✓Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share2.51x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change-20.0%✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+1.2558; #1534/5247 (top 29.2%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization+2.99%; #2045/4519 (top 45.3%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date✗OshaughnessyTop 10% of eligible cross-section - Verdicts8% pass✓ 1✗ 11▾
Split decision: 10 FAIL · 5 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (3/9)✗BuffettFAIL (2/9)✗LynchFAIL (1/7)✗GreenblattRank #1201•PiotroskiNEUTRAL (F-Score 7)✗DremanFAIL (2/11)•MungerNEUTRAL (3/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (3/5)✗AckmanFAIL (3/9)✓TempletonPASS (4/8)•SleepNEUTRAL (4/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (3/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked) - Valuation models11% pass✓ 1✗ 8▾
Models split on CVGW at $27.63 — fair values range $2.90–$28.39
Graham fair value$17.00✗Graham-62.5% margin vs $27.63Buffett fair value$16.69✗Buffett-65.5% margin vs $27.63Greenblatt fair value$7.15✗Greenblatt-286.4% margin vs $27.63Dreman fair value$2.90✗Dreman-852.8% margin vs $27.63Munger fair value$10.88✗Munger-154.0% margin vs $27.63Pabrai fair value$12.54✗Pabrai-120.3% margin vs $27.63Akre fair value$28.39✓Akre+2.7% margin vs $27.63Marks fair value$10.52✗Marks-162.6% margin vs $27.63Ackman fair value$11.11✗Ackman-148.7% margin vs $27.63 - Growth13% pass✓ 3✗ 10▾
7 of 8 flag CVGW's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -5.3% vs Rev: -10.5%✗LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency21/27 years positive✓MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-2.0%✗Ackman>= 5%Positive EPS Growth Frequency4/5 years with positive EPS growth✓AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 10.5% -> 9.8%, operating margin 2.1% -> 3.0%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR-9.4%✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR190.8% over 5 years✗Neff7%-20% annualized - Cash Flow50% pass✓ 6✗ 6▾
5 of 10 pass — Lynch, Dreman, Pabrai +2 more object
Free Cash Flow Proxy$25.1M✓BuffettPositive and growingFCF Positive and Growing$14.7M✗LynchPositive and growingOperating Cash Flow$21.5M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=7.37%, ROA=6.77%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)22.9x✗Dreman< 8xP/E or FCF YieldP/E=24.9x, FCF Yield=4.0%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive18/19 years FCF positive✓MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap3.0%✗Ackman>= 4%Price / FCF per Share25.5x✗Ackman<= 25Positive Operating Cash Flow frequency24/25 years positive✓SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$14.7M✓Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization+2.99%; #2045/4519 (top 45.3%)✗OshaughnessyTop 10% of eligible cross-section - Efficiency50% pass✓ 5✗ 6▾
4 of 8 pass — Buffett, Munger, Akre +1 more object
Current Ratio2.21✓Graham>= 2.0ROIC (3-5 yr avg)4.4%✗Buffett> 10%ROIC - WACC-5.6%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)25.4%✓Greenblatt> 25%Current Ratio Change YoY2.17 -> 2.47✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY2.20x -> 2.22x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities2.21✓Dreman> 1.5Return on Invested Capital4.9%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=3.9%; FY2024: ROIC=6.4%; FY2025: ROIC=7.3%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC0.6% (RR=11% x ROIC=4.9%)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest 7.3%)✗SleepROIC > 12% in a majority of years
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 0.2% of shares last year, 0.4% issued over two.
- Buybacks
- —
- Dividends
- $14.3M
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-01-31 2025-02-01 – 2026-01-31 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex, dividends paid, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense. | Q1 FY 2026 2025-11-01 – 2026-01-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|
| Market Cap | $490.7Mcurrent | -- | $450.6Mest. | $391.9Mest. | $437.4Mest. | $529.5Mest. | $676.5Mest. |
| Revenue | $616.3M↓10% | $122.2M↓21% | $648.4M↓2% | $661.5M↑11% | $594.1M↓23% | $769.7M↓27% | $1.1B |
| Operating Income | $13.1M↓47% | -$1.4M↓129% | $19.6M↑17% | $16.7M↑37% | $12.2M↑80% | $6.8M↑168% | -$10.0M |
| Net Income | $16.1M↑68% | $732.0K↓83% | $19.8M↑1940% | -$1.1M↑87% | -$8.3M↓34% | -$6.2M↑47% | -$11.8M |
| EPS (Diluted) | -- | $0.04↓84% | $1.11↑1950% | $-0.06↑87% | $-0.47↓34% | $-0.35↑48% | $-0.67 |
| Gross Margin | 10.2%↓3% | 12.4%↑22% | 9.8%↓4% | 10.2%↓3% | 10.5%↑48% | 7.1%↑31% | 5.4% |
| Operating Margin | 2.1%↓40% | -1.2%↓136% | 3.0%↑20% | 2.5%↑23% | 2.1%↑133% | 0.9%↑193% | -0.9% |
| ROE | 7.8%↑65% | — | 9.6%↑1881% | -0.5%↑86% | -4.0%↓42% | -2.8%↑46% | -5.2% |
| Total Debt | $4.7M↓4% | $4.7M↓4% | $4.9M↓4% | $5.1M↓86% | $35.9M↑495% | $6.0M↓16% | $7.1M |
| Shareholders' Equity | $205.7M↑1% | $205.7M↑1% | $206.9M↑3% | $200.3M↓5% | $210.2M↓6% | $223.4M↓2% | $226.9M |
| Current Ratio | 2.21↓1% | 2.21↓1% | 2.47↑14% | 2.17↑33% | 1.63↑32% | 1.23↓7% | 1.33 |
| Debt / Equity | 0.02↓5% | 0.02↓5% | 0.02↓7% | 0.03↓85% | 0.17↑533% | 0.03↓14% | 0.03 |
| Operating Cash Flow | $17.3M↓13% | -$8.7M↓96% | $21.5M↓12% | $24.4M↑269% | -$14.5M↓129% | $50.2M↑270% | $13.6M |
| Free Cash Flow | $14.7M↓18% | -$9.4M↓101% | $19.4M↓10% | $21.5M↑186% | -$25.2M↓162% | $40.5M↑1796% | $2.1M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Agriculture
CVGW vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corteva, Inc.CTVA | $6.3B | $9.43 | $17.4B | $1.1B | 4.5% | 0.11 | — | 1.43 | 5/9 | 2/9 | 4/7 | 3/3 | F-Score 7 | 9/11 |
| CAL-MAINE FOODS INCCALM | $3.1B | $66.45 | $2.9B | $316.7M | 12.0% | — | 12.0% | 7.70 | 6/9 | 3/9 | 2/7 | 1/3 | F-Score 6 | 6/11 |
| Dole plcDOLE | $1.3B | $14.32 | $9.2B | $51.3M | 3.8% | 0.63 | 2.4% | 1.17 | 4/9 | 1/9 | 0/7 | 1/3 | F-Score 6 | 3/11 |
| Adecoagro S.A.AGRO | $1.3B | $9.11 | $1.5B | $92.3M | 6.7% | 0.57 | 12.0% | 2.54 | 5/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 6/11 |
| DEL MONTE CORPDMC | $1.3B | $27.22 | $4.3B | $90.7M | 4.5% | 0.09 | 3.2% | 2.16 | 5/9 | 1/9 | 2/7 | 0/3 | F-Score 8 | 6/11 |
| Mission Produce, Inc.AVO | $1.0B | $11.83 | $1.4B | $37.7M | 6.4% | 0.16 | 4.7% | 1.95 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 8 | 3/11 |
| BrasilAgro - Brazilian Agricultural Real Estate CoLND | $311.8M | $3.13 | $160.2M | $25.2M | 6.3% | — | 23.5% | — | 5/9 | 3/9 | 0/7 | 1/3 | F-Score 5 | 4/11 |
| Verano Holdings Corp.VRNO | $296.8M | $4.07 | $821.5M | $257.9M | -36.6% | 0.57 | -13.0% | 2.88 | 2/9 | 0/9 | 2/7 | 0/3 | F-Score 5 | 2/11 |